SCHEMBL9989458

SCHEMBL9989458

Cc1ccc(S(=O)(=O)n2ccc3c(NC4CCCCC4)c(N)cnc32)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.41
ALDH1A1 P00352 6/20 0.40
CYP3A4 P08684 1/20 0.40
TSHR P16473 1/20 0.40
LMNA P02545 2/20 0.39
EPHX2 P34913 1/20 0.39
NOD2 Q9HC29 1/20 0.39
NOD1 Q9Y239 1/20 0.39
TP53 P04637 3/20 0.38
CCR6 P51684 2/20 0.38
HTR6 P50406 3/20 0.37
KDM4E B2RXH2 1/20 0.36
PKM P14618 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
MAPT P10636 2/20 0.36
GLA P06280 1/20 0.36
KMT2A Q03164 1/20 0.36
PDE4B Q07343 1/20 0.36
GAA P10253 2/20 0.35
KCNH2 Q12809 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15203404 0.90 L3MBTL1 (0.42) L3MBTL1ALDH1A1CYP3A4TSHRLMNA
SCHEMBL2222165 0.90 PDE4B (0.43) EPHX2HTR6KDM4EMAPTPDE4B
SCHEMBL29809747 0.90 PDE4B (0.43) EPHX2HTR6KDM4EMAPTPDE4B
SCHEMBL26246793 0.89 PDE4B (0.41) EPHX2HTR6KDM4EMAPTPDE4B
SCHEMBL1933897 0.87 KDM4E (0.40) L3MBTL1ALDH1A1CYP3A4TSHRLMNA
SCHEMBL30811342 0.87 L3MBTL1 (0.40) L3MBTL1ALDH1A1NOD1CCR6HTR6
SCHEMBL23061211 0.86 NOD2 (0.40) L3MBTL1ALDH1A1CYP3A4TSHRLMNA
SCHEMBL9991927 0.85 CDK2 (0.39) L3MBTL1ALDH1A1CYP3A4TSHRLMNA
SCHEMBL20706502 0.85 L3MBTL1 (0.39) L3MBTL1ALDH1A1CYP3A4TSHRLMNA
SCHEMBL28637052 0.85 L3MBTL1 (0.39) L3MBTL1ALDH1A1CYP3A4TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3950692-A1 NOVEL TRICYCLIC COMPOUNDS AbbVie Inc. (US) 2022-02-09 EP disclosed
EP-3950692-A1 NOVEL TRICYCLIC COMPOUNDS AbbVie Inc. (US) 2022-02-09 EP disclosed
US-20210061813-A1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC. (US) 2021-03-04 US disclosed
US-20210061813-A1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC. (US) 2021-03-04 US disclosed
US-RE47221-E1 Tricyclic compounds ABBVIE INC. (US) 2019-02-05 US disclosed
US-RE47221-E1 Tricyclic compounds ABBVIE INC. (US) 2019-02-05 US disclosed
EP-3266786-A1 NOVEL TRICYCLIC COMPOUNDS AbbVie Inc. (US) 2018-01-10 EP disclosed
EP-2506716-B1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC (US) 2017-05-17 EP disclosed
EP-2506716-B1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC (US) 2017-05-17 EP disclosed
US-20160222020-A1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC. (US) 2016-08-04 US disclosed
US-20160222020-A1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC. (US) 2016-08-04 US disclosed
US-20130216497-A1 NOVEL TRICYCLIC COMPOUNDS ABBOTT LABORATORIES 2013-08-22 US disclosed
US-20130216497-A1 NOVEL TRICYCLIC COMPOUNDS ABBOTT LABORATORIES 2013-08-22 US disclosed
US-20130216497-A1 NOVEL TRICYCLIC COMPOUNDS ABBOTT LABORATORIES 2013-08-22 US disclosed
US-8426411-B2 Tricyclic compounds ABBOTT LABORATORIES (US) 2013-04-23 US disclosed
US-8426411-B2 Tricyclic compounds ABBOTT LABORATORIES (US) 2013-04-23 US disclosed
US-20110311474-A1 Novel Tricyclic Compounds ABBOTT LABORATORIES (US) 2011-12-22 US disclosed
US-20110311474-A1 Novel Tricyclic Compounds ABBOTT LABORATORIES (US) 2011-12-22 US disclosed
US-20110311474-A1 Novel Tricyclic Compounds ABBOTT LABORATORIES (US) 2011-12-22 US disclosed
WO-2011068881-A1 NOVEL TRICYCLIC COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210061813-A1 NOVEL TRICYCLIC COMPOUNDS CYP11B2, CYP11B1, ABCB1 L3MBTL1 4591/4885ALDH1A1 340/4885CYP3A4 11/4885
US-20160222020-A1 NOVEL TRICYCLIC COMPOUNDS CYP11B2, CYP11B1, ABCB1 L3MBTL1 4591/4885ALDH1A1 340/4885CYP3A4 11/4885
US-20110311474-A1 Novel Tricyclic Compounds CYP11B2, CYP11B1, ABCB1 L3MBTL1 4591/4885ALDH1A1 340/4885CYP3A4 11/4885
US-20130216497-A1 NOVEL TRICYCLIC COMPOUNDS CYP11B2, CYP11B1, ABCB1 L3MBTL1 4591/4885ALDH1A1 340/4885CYP3A4 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.